NCT02416869

Brief Summary

The aim of this randomized double-blind cross over clinical trial is to investigate effectiveness of different routes of applications (intramuscular and submucous at the site of surgery) and doses (4 mg and 8 mg) of Dexamethasone on swelling, trismus, pain and quality of life after lower third molar surgery.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for phase_4

Timeline
Completed

Started Jan 2014

Longer than P75 for phase_4

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2014

Completed
1.2 years until next milestone

First Submitted

Initial submission to the registry

April 2, 2015

Completed
13 days until next milestone

First Posted

Study publicly available on registry

April 15, 2015

Completed
4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2019

Completed
Last Updated

April 22, 2019

Status Verified

April 1, 2019

Enrollment Period

5.2 years

First QC Date

April 2, 2015

Last Update Submit

April 19, 2019

Conditions

Keywords

DexamethasoneLower third molar surgery

Outcome Measures

Primary Outcomes (1)

  • Facial swelling (using 3 facial measurements (in millimeters)

    We followed facial swelling 1, 3 and 7 days after intervention. Swelling in the operation site will be evaluated using 3 facial measurements (in millimeters): 1. Tragus - Midline. 2. Tragus - Corner of the mouth 3. Gonion - Lateral canthus.

    1 day, 3 day, 7 day

Secondary Outcomes (3)

  • Postoperative pain (visual analog scale)

    1 day, 3 day, 7 day

  • Postoperative trismus (difference in interincisal distance at the maximal mouth opening (in millimeters) before and after surgery)

    1 day, 3 day, 7 day

  • Postoperative discomfort (25-items custom made questionnaire)

    4 day, 7 day

Study Arms (6)

Intramuscular application

ACTIVE COMPARATOR

Intramuscular application of 4mg Dexamethasone

Procedure: Intramuscular application

Submucosal application

EXPERIMENTAL

Submucosal application of 4mg Dexamethasone

Procedure: Submucosal application

4mg Dexamethasone submucosal

ACTIVE COMPARATOR

4mg Dexamethasone submucosal application

Drug: 4mg Dexamethasone submucosal

8mg Dexamethasone submucosal

EXPERIMENTAL

8mg Dexamethasone submucosal application

Drug: 8mg Dexamethasone submucosal

4mg Dexamethasone postoperative

ACTIVE COMPARATOR

4mg Dexamethasone postoperative application

Procedure: 4mg Dexamethasone preoperative

4mg Dexamethasone preoperative

EXPERIMENTAL

4mg Dexamethasone postoperative application

Procedure: 4mg Dexamethasone postoperative

Interventions

Patient receive 4mg of Dexamethasone by intramuscular application

Intramuscular application

Patients receive 4mg of Dexamethasone by submucosal application

Submucosal application

Patients receive 4mg of submucosal Dexamethasone

Also known as: Dexasone
4mg Dexamethasone submucosal

Patients receive 8mg of submucosal Dexamethasone

Also known as: Dexasone
8mg Dexamethasone submucosal

Patients receive 4mg of Dexamethasone preoperatively

4mg Dexamethasone postoperative

Patients receive 4mg of Dexamethasone postoperatively

4mg Dexamethasone preoperative

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Healthy patients (ASA I)
  • Bilateral symmetrically impacted lower third molars according to Pel-Gregory's and Winter's classification

You may not qualify if:

  • Heavy tobacco smokers
  • Drug and / or alcohol abusers

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

School of Dental Medicine

Belgrade, 11000, Serbia

Location

MeSH Terms

Interventions

Dexamethasone

Intervention Hierarchy (Ancestors)

PregnadienetriolsPregnadienesPregnanesSteroidsFused-Ring CompoundsPolycyclic CompoundsSteroids, Fluorinated

Study Officials

  • Miroslav M Andric, DDS, PhD

    University of Zagreb

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor

Study Record Dates

First Submitted

April 2, 2015

First Posted

April 15, 2015

Study Start

January 1, 2014

Primary Completion

April 1, 2019

Study Completion

April 1, 2019

Last Updated

April 22, 2019

Record last verified: 2019-04

Locations